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Recent findings implicating TRPM7 and TRPM2 in oxidative stress-induced neuronal death thrust these channels into the spotlight as possible
therapeutic targets for neurodegenerative diseases. In this review, we describe how the functional properties of TRPM7 and TRPM2 are
interconnected with calcium (Ca2+) and magnesium (Mg2+) homeostasis, oxidative stress, mitochondrial dysfunction, and immune mechanisms,
all principal suspects in neurodegeneration. We focus our discussion on Western Pacific Amyotrophic Lateral Sclerosis (ALS) and Parkinsonism
Dementia (PD) because extensive studies conducted over the years strongly suggest that these diseases are ideal candidates for a gene-
environment model of etiology. The unique mineral environment identified in connection with Western Pacific ALS and PD, low Mg2+ and Ca2+,
yet high in transition metals, creates a condition that could affect the proper function of these two channels.
© 2007 Elsevier B.V. All rights reserved.Keywords: TRPM7; TRPM2; Western Pacific ALS; Parkinsonism Dementia; Oxidative stress; Neurodegeneration; Ca2+ and Mg2+ homeostasis; Mitochondrial
dysfunction; Microglial activation1. Western Pacific ALS and PD
Amyotrophic lateral sclerosis (ALS), a fatal disease
characterized by the progressive degeneration of motor neurons,
is among the most common of adult onset neurodegenerative
diseases [1]. The underlying pathogenic processes are not
known but are believed to be due to a multitude of contributory
factors including genetic predisposition, environmental toxins,
aberrant cellular calcium and metal ion homeostasis, oxidative
stress, mitochondrial dysfunction, and inflammatory reactions
[2,3]. More than 50 years ago, an unusually high incidence of
ALS was reported in three geographically separate areas in the
Western Pacific: the islands of Guam and Rota, the Kii
Peninsula of Japan, and southern West New Guinea [4–6]. On
Guam, the incidence rate of ALS in 1954 was estimated to be
50–100 times higher than the worldwide incidence [7]. A
related but distinct neurodegenerative disorder, parkinsonism
dementia (PD), characterized by the clinical manifestation of⁎ Corresponding author. Tel.: +1 808 956 5212; fax: +1 808 956 6984.
E-mail address: meredith@pbrc.hawaii.edu (M.C. Hermosura).
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doi:10.1016/j.bbadis.2007.02.008both parkinsonism and dementia in the same patient, was also
prevalent in the same three Western Pacific ALS foci [5–9].
These two disorders can have overlapping clinical symptoms,
frequently occur together in the same families and even in the
same individual, have neurofibrillary tangle-bearing neurons in
the brain and spinal cord, and both are progressive, and
eventually fatal [10–12]. While two opposing views exist as to
whether Western Pacific ALS and PD are separate diseases or
clinical variants of the same disease, there is general agreement
that the basic pathogenic mechanisms underlying these
disorders are similar. Since the topic of this review is
mechanistic in nature, Western Pacific ALS and PD will be
considered as one (ALS/PD), except where it is absolutely
necessary to consider them separately.
The hyperendemic ALS/PD foci in the Western Pacific
attracted considerable interest among medical researchers and
scientists for a variety of reasons including the fact that these
foci of ALS/PD are ideal for studying the relative contributions
of genes and environment in disease etiology because each
disease focus occurs in a defined, restricted environment among
the three genetically different homogeneous groups of people.
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and deserve to be investigated for those reasons alone. In
addition, ALS/PD foci in these areas are extremely informative
disease clusters that could provide valuable leads to the
pathologic mechanisms underlying the more common, sporadic
forms of ALS, Parkinson's Disease (PD), and Alzheimer's
Disease (AD) worldwide.
In 1956, the National Institute of Neurological Diseases and
Blindness (NINDB) as it was then called, of the National
Institutes of Health (NIH), established a research center on
Guam to investigate the clinical, epidemiologic, neuropatholo-
gical, and genetic aspects of ALS/PD. The intensive research
that followed did not yield a clear understanding of disease
etiology, but nevertheless suggested that a complex interplay
between genetic susceptibility and exposure to specific
environmental factors were involved. Extensive epidemiologi-
cal studies subsequently identified two candidate environmental
triggers: (1) altered mineral content of the soil and drinking
water coupled with abnormal mineral metabolism [13,14]; and
(2) toxins of the cycad plant, a traditional food source in Guam
[15,16].
2. The environmental factors
2.1. Altered mineral content in the environment
All three high incidence foci in the Western Pacific were
reported to have severely low levels of calcium (Ca2+) and
magnesium (Mg2+), coupled with high levels of bioavailable
transition metals such as manganese (Mn2+), aluminum (Al3+),
and iron (Fe3+). Soil and rivers in areas of high incidence in the
Kii Peninsula were found to contain high levels of Mn2+ but
very low levels of Ca2+ and Mg2+ [13]. On Guam, the highest
incidence of ALS/PD occurred in the southern part of the island,
the same area where Ca2+ levels in the soil and traditional spring
drinking water were found to be 10- to 100-fold lower
compared with other regions of the island. Mg2+ in the water
supply is similarly low, about 10-fold lower in the South than
elsewhere in Guam [14]. The levels of Ca2+ and Mg2+ in soil
and drinking water in the high incidence villages in West New
Guinea were even lower than those seen in southern Guam [5].
The unusual similarity of the mineral composition in these three
ALS/PD foci led to the proposal that prolonged exposure to
such an environment could be involved in the pathogenesis of
ALS/PD [13]. This hypothesis is supported by findings of
altered Ca2+ and Vitamin D metabolism [17]; hypocalcemia and
reduction of critical bone mass [18]; and the accumulation of
Ca2+, and transition metals such as Al3+, Fe2+, Mn2+ and Zn2+
in the brain and spinal cord of patients afflicted with ALS/PD in
Guam and Kii peninsula [19–23]. Animal models fed altered
mineral diets mimicking the environmentally observed Ca2+,
Mg2+, Mn2+ and Al3+ levels, showed evidence of altered Ca2+
homeostasis and deposition of Ca2+, Mn2+, Al3+ in the brain
and spinal cord tissues [24–26]. These models also showed
signs of neuronal damage including neurofibrillary pathology
and mitochondrial degeneration. In a recent study, rats were
exposed to low Ca2+ and /or Mg2+ intake over two generationsin order to simulate human conditions in Guam more closely
[27]. Of the various combinations of Ca2+ and Mg2+ contents
tested, exposure to lowMg2+ (one fifth of the normal level), was
more deleterious, causing significant loss of dopaminergic
neurons in the substantia nigra. We will offer a possible
mechanistic explanation of these observations later in this
review.
2.2. L-beta-N-methylamino-L-alanine (L-BMAA) is a putative
neurotoxin from the cycad plant
Traditionally used as a food source in Guam and for
medicinal applications in Kii Peninsula and West New Guinea,
cycad and its toxin, L-BMAA, is the second environmental
factor that was proposed to be involved in the pathogenesis of
ALS/PD [15,16]. It is also one of the most controversial topics
in ALS/PD research. L-BMAA is a non-protein amino acid
present in cycad seeds that has been shown to possess
neurotoxic properties in cell culture models [28,29]. Impor-
tantly, macaque (Cynomolgus) monkeys fed large doses of
L-BMAA exhibited clinical and neuropathological ALS-like
symptoms [15]. The massive dose used, however, was
considered unrealistic in terms of human consumption because
very low amounts of L-BMAA remain in washed cycad flour,
considered the primary source of human exposure [30,31].
Weak neurotoxic properties detected in cell culture studies
further substantiated the view that L-BMAA may not sig-
nificantly contribute to ALS/PD pathogenesis. High (milli-
molar) concentrations of L-BMAA were needed to induce
cytotoxic effects in cultured neuronal cells [28]. NMDA
receptor (NMDAR) antagonists largely blocked these effects
suggesting that L-BMAA acts via NMDARs [32,33]. It was
further shown that the addition of bicarbonate ions considerably
increased the potency of L-BMAA due to the formation of β-
carbamate, a structurally more potent agonist of NMDARs [32].
While nuclear magnetic spectroscopy (NMR) could indeed
demonstrate that carbamate compounds form when BMAA and
bicarbonate are mixed, it must be stressed that, as far as is
known, no study has ever reported the isolation of carbamates
from brain or spinal cord tissues of ALS/PD patients.
Subsequent studies indicate that NMDAR activation may
not be the dominant pathway through which L-BMAA exerts its
neurotoxic effects. L-BMAA was reported to preferentially
interact with metabotropic receptors [34–36], and non-NMDA
receptors in the presence of bicarbonate [37,38]. Preferential
injury to NADPH-diaphorase neurons induced by lower
BMAA exposures was found to be predominantly mediated
by AMPA/kainate receptors [28,32]. Exposure to L-BMAA
(and bicarbonate) increased intracellular Ca2+, [Ca2+]i, levels
suggesting Ca2+ involvement [39]. Since AMPA/kainate recep-
tors are Ca2+-impermeable, the involvement of these receptors
was not easy to integrate into the prevailing hypothesis of L-
BMAA toxicity. However, it was soon discovered that a special
class of AMPA/kainate receptors, Ca-A/K, which are Ca2+-
permeable, exists [40,41]. Of particular relevance to ALS,
motor neurons (MNs) were shown to possess large numbers of
Ca-A/K channels [42].
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could potentially serve as an endogenous neurotoxic reservoir
of this toxin [43], the issue of L-BMAA neurotoxicity was
recently reexamined by Rao et al. [44]. Spinal neurons plated
on an astrocytic monolayer were exposed to controlled doses of
L-BMAA, cycad extracts, and the antagonists NBQX (specific
for AMPA/kainate receptors) and Mk801 (an NMDAR
antagonist). Cell death, [Ca2+]i changes, and reactive oxygen
species (ROS) production were monitored. Results showed
L-BMAA to be more potently toxic to MNs than to all other
spinal neurons. Moreover, L-BMAA caused substantially
greater [Ca2+]i, rises and ROS generation in MNs than in the
other spinal neurons. The addition of NBQX, but not Mk801,
conferred substantial protection, suggesting that L-BMAA
toxicity is predominantly mediated through Ca-A/K channels.
Nevertheless, NBQX was not completely protective. In motor
neurons exposed to 100 μM L-BMAA, NBQX or a combina-
tion of NBQX and Mk801 reduced L-BMAA-induced cell
death by two-thirds, suggesting the involvement of other
pathways. Interestingly, an earlier study using cultured
hippocampal neurons showed that exposure to L-BMAA
activated an unidentified linear current [38]. It is possible that
this current is carried by TRPM2, one of the channels covered
in this review, because increased [Ca2+]i and ROS promote
TRPM2 activation.
The Rao et al. study reported three important findings: (1)
motor neurons are selectively more vulnerable to L-BMAA
toxicity; (2) these toxic effects are possibly mediated through
[Ca2+]i rises via Ca-A/K channels and other pathways, and the
accompanying generation of ROS; and (3) L-BMAA, at
concentrations found in cycad extracts, exert neurotoxic effects.
The demonstration that relatively low (tens of micromolar)
levels of L-BMAA could damage motor neurons firmly puts L-
BMAA as a valid candidate in the etiology of ALS/PD.
Nevertheless, it must be stressed that L-BMAAwas not found in
all ALS/PD autopsy specimens and that another study
conducted by a separate research group tested for, but did not
detect, free L-BMAA in Alzheimer's Disease patients from the
US Pacific Northwest nor in Guam PD patients or Chamorro
controls [45]. For the purposes of this review, the important
point is that L-BMAA causes [Ca2+]i rises and ROS generation
in motor neurons, creating conditions conducive to the
activation of TRPM2, an ion channel that has been linked to
oxidative stress-mediated neuronal death [46,47].
3. The question of genetic predisposition
Epidemiological studies have implicated genetic factors in
the development of ALS/PD because cases cluster in families—
siblings and parents of afflicted patients were found to be at
increased risk of developing these diseases [48]. An intensive
effort was launched to identify the genetic cause of ALS/PD,
including pedigree analyses and calculation of inbreeding
coefficients in high incidence villages, identification of selected
gene markers such as HLA antigens, blood group systems, red
cell enzymes, immunoglobulin allotypes, and serum proteins
[49]. None yielded satisfactory answers.A prospective case-control registry was established in 1958
(completed in 1963) to determine if first-degree relatives and
spouses of patients with ALS/PD have a higher risk of
developing the disease than relatives of unaffected controls
(matched for age, sex, and village). A 25-year follow-up study
revealed significantly increased risk of developing ALS and PD
among siblings, and to a lesser extent, among spouses of
patients [50]. Offsprings, however, were not found to have
increased risk in the 25-year follow-up study probably because
most were below the age of risk for both diseases. Siblings of
controls did not have increased risk and have, in fact, lower risk
than the general Chamorro population. A more recent 40-year
follow-up showed similar results: first-degree relatives of ALS
or PD patients have a significantly higher risk of developing
either disease than the Guamanian population whereas relatives
of controls have significantly lower risks [51]. There is,
however, a notable difference because this time, offsprings of
PD patients were found to have increased risk of developing
either ALS or PD. While these data suggest a genetic
contribution to etiology, simple Mendelian rules do not apply.
For one, both 25-year and 40-year follow-up studies demon-
strated increased risk for spouses of patients. Additionally, the
40-year study found an increase in age-of-onset and a dramatic
decline in incidence for both diseases since the 1950's when the
first systematic epidemiological studies commenced. The
decline was coincident with increasing modernization of
Guam that changed lifestyles, changed access to locally
grown foods and changed or improved local drinking water
supplies. These findings, especially the rapid decline over three
decades in southern Guam, where the highest incidence of
disease is found, strongly suggest that environmental factors
contribute to the etiology [52,53]. In support of this conclusion,
segregation analysis performed on the registry data that were
used in the 25-year follow-up study, including all patients from
1950 to 1983, rejected a purely environmental hypothesis and a
Mendelian dominant or a Mendelian recessive hypothesis, but
could not reject a two-allele additive major locus hypothesis
[54]. This segregation study therefore proposed that a major
gene in combination with environmental factors could be
involved in the development of ALS/PD.
3.1. A search for candidate genes
In an effort to identify the genes that are involved in the
etiology of ALS/PD, those genes that have previously been
linked to familial ALS, PD, or AD were sequenced. No disease-
associated variant or mutation was found after sequence
analyses of Cu–Zn superoxide dismutase, SOD1 (familial
ALS), the microtubule-associated protein tau, TAU (PD),
apolipoprotein E, ApoE Σ4 (early-onset AD) and CYP2D6,
which encodes a detoxifying enzyme (PD) [55–58].
It is likely that what we should be looking for are
susceptibility genes that do not directly cause disease but
contribute predisposition when functioning in a conducive
environment. Importantly, the genetic causation of complex
diseases like ALS/PD is likely polygenic in nature, that is,
minor functional variants of several genes could together
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susceptibility genes for ALS/PD, we decided that an effective
approach would be to use the environmental risk factors found
in all three hyperendemic Western Pacific foci as a screening
tool. What gene product's function will most likely be affected
by low Mg2+, low Ca2+, and high transition metals? Foremost
among several functional candidates are ion channel genes. In
order to narrow the field further, we imposed two additional
limitations: the candidate channel/s must be expressed in the
central nervous system (CNS) and be affected by oxidative
stress. Oxidative stress is the price that a eukaryotic cell pays for
being able to use molecular oxygen (O2) as an energy source.
Oxidative phosphorylation, the process of converting energy
from O2 to a form that can be used by the cell, produces high-
energy by-products, ROS, which are normally managed by the
cellular antioxidant defense system. Oxidative stress results
when the balance tilts heavily in favor of ROS production such
as occurs in conditions of high metabolic rates, weakened
cellular defense, and presence of environmental toxins such as
transition metals. Such imbalance leads to molecular damage,
failure of cellular functions, and ultimately cell death. Increased
oxidative stress happens as a consequence of aging, the
universal risk factor for all neurodegenerative diseases. In the
hyperendemic ALS/PD foci in the Western Pacific, the unique
mineral composition of the environment creates a condition of
increased oxidative stress because low Mg2+ levels cause lipid
peroxidation [59] while transition metals act as redox catalysts
causing increased ROS production [60].
We found two candidate genes that meet our criteria-ion
channels that are expressed in the brain and affected by
oxidative stress: TRPM7 and TRPM2. Both belong to the
transient receptor potential melastatin (TRPM) family of
channels. TRPM7 resides in chromosome 15q21, within a
locus that has been linked to a form of autosomal recessive
familial ALS [61]. TRPM2 is located in disease-rich chromo-
some 21 (21q22.3), near the SOD1 locus (21q22.1–22.2) that
has been associated with familial ALS [62].
4. TRPM7
TRPM7 is a ubiquitously expressed plasma membrane
protein that conducts virtually all divalent ions—from the
physiologically abundant Ca2+ and Mg2+, to essential trace
metals such as Mn2+ and Zn2+ and non-essential, even toxic
transition metals such as Cd2+ [63,64]. It was proposed that
TRPM7 plays a central role in regulating cellular homeostatic
levels of Ca2+, Mg2+ and trace metals [63–65]. TRPM7 is
required for cell viability as evidenced by the resulting lethal
phenotype when the channel is knocked out in DT40 B
lymphocytes [63]. Studies have implicated TRPM7 involve-
ment in various cell functions including cell growth, prolifera-
tion, embryonic development, anoxic neuronal death,
pathological response to vessel wall injury, actomyosin
contractility, and neurotransmitter release in sympathetic
neurons [65–72]. Perhaps of particular relevance to the topic
of this review is the recent report implicating TRPM7 in familial
Alzheimer's disease [73].TRPM7 is a dual-function protein, one of only three known
channels possessing both a channel and an enzyme domain, the
other two being TRPM6 and TRPM2. TRPM7 and TRPM6
show approximately 50% sequence homology and both possess
a C-terminal serine/threonine alpha (α)-kinase [74]. α-kinases
are characterized by their unique ability to phosphorylate
substrates within α-helices, as opposed to conventional protein
kinases which phosphorylate their substrates within loops, β-
turns and irregular structures [75,76]. Biochemical studies have
shown kinase activity in both TRPM6 and TRPM7 [65,77,78].
The relationship between a channel and a kinase moiety
coexisting in the same molecule has justifiably been the subject
of considerable interest. It was initially thought that TRPM7
kinase activity regulates channel function [77] but subsequent
studies have demonstrated that phosphotransferase activity is
not required for channel activity [78,79]. TRPM7 was recently
implicated in the regulation of cell adhesion and podosome
formation by modulating actomyosin contractility through
phosphorylation of the myosin IIA heavy chain [72]. Annexin
1, a Ca2+-regulated phospholipid binding protein, has also been
identified as a substrate for TRPM7 kinase [80]. Phosphoryla-
tion of annexin 1 and the myosin IIA heavy chain by TRPM7
kinase requires Ca2+ influx through the channel domain,
indicating an intricate association between channel and kinase
functions [72,80]. It has thus been suggested that ions
permeating the pore regulate kinase function and the subsequent
recruitment or activation of downstream signaling components
[72]. This is an attractive hypothesis that definitely merits
further investigation.
4.1. TRPM7 regulation
TRPM7 channels are constitutively open but inhibited
intracellularly by free Mg2+ [63,81], a fact reflected in one of
the names accorded to endogenous TRPM7 currents, MIC for
Mg2+-inhibited current [82]. The other terminology, MagNuM
(Magnesium Nucleotides Metal) takes into account block by
Mg2+ and Mg2+-nucleotides (primarily MgATP) and metal
permeation [81]. TRPM7 also responds to changes in pH
[83,84], a feature that may be relevant during certain
pathological conditions such as when acidosis occurs during
ischemia. In addition to intracellular free Mg2+, MgATP and
pH, other modulators of channel activity have been suggested in
various experimental systems: phospholipase C-coupled recep-
tors acting through phosphatidylinositol 4,5-bisphosphate
(PIP2), cyclic adenosine 3,5-monophosphate (cAMP), poly-
valent cations, and phosphorylation by TRPM6 [78,85–89].
4.2. Mg2+ and Ca2+ are permeant blockers
In addition to inhibiting TRPM7 from the cytoplasmic side,
Mg2+ also plays a crucial role in regulating external ion
permeation through these channels. This effect of Mg2+ is of
paramount physiological relevance because external Mg2+
affects the permeation of other ions. This channel is cation
nonselective, and yet, the TRPM7 I/V curve under physiolo-
gical ionic conditions is characterized by pronounced outward
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potentials, and increasingly large outward currents at positive
voltages. The reason for this is external divalent block, divalents
present in the extracellular medium (physiologically Mg2+ and
Ca2+) produce a voltage-dependent block that is progressively
removed by depolarization. Divalent block is also relieved at
very negative voltages. Kerschbaum et al. [89] conducted a
detailed study of the external divalent (and polyvalent) block
and presented a model for ion permeation through MIC/TRPM7
channels. The model successfully predicted experimentally
observed effects of Mg2+ on the permeation of monovalent
cations. It proposed the presence of two low-affinity binding
sites and a single high-affinity site within the conducting region
of the channel. According to this model, when present at low
μM concentrations, Mg2+ and Ca2+ displace Na+ from the high-
affinity binding site thereby blocking the monovalent current.
Mg2+ binds to this site more strongly than Ca2+ (K1/2 at
−40 mV is 1 μM for Mg2+ vs. 4 μM for Ca2+) indicating that it
is the stronger blocker. Permeation of Mg2+ and Ca2+ occurs
when either is present at sufficiently high concentrations,
possibly by a ‘knock off’mechanism involving the high-affinity
binding site, and ‘punch-through’ of the blocking ion to the
inside.
Whether there is one binding site or more, it is important to
bear in mind that Mg2+, Ca2+, and Na+ likely interact in the
pore, competing for binding sites, each influencing the others.
While Mg2+ and Ca2+ impose strong block of Na+ permeation,
the block is not total because some degree of Na+ permeation
have been observed [67,82]. The experimentally determined
binding affinities show that Mg2+ is the stronger blocker,
suggesting that it will be harder for a Ca2+ ion to displace a
bound Mg2+ ion than vice versa. It can thus be envisioned that
as the extracellular Mg2+ concentration is reduced, the ability of
Ca2+ (and Na+) to enter the channel will correspondingly
increase. Moreover, removal of Mg2+ from the external solution
altogether (as is done in some experiments, particularly
excitotoxicity assays) will favor the increased influx of Ca2+
through TRPM7. Indeed, we observed increased Ca2+ influx
through overexpressed murine TRPM7 as external Mg2+ con-
centration is reduced (Hermosura et al., unpublished data).
Following this line of reasoning, removal of bothMg2+ and Ca2+
from the external solution will remove divalent block, allowing
monovalent (Na+) influx. This has been demonstrated in patch
clamp experiments [67,81,89].
5. TRPM7 and neuronal death
TRPM7 has recently been implicated in anoxic neuronal
death by mediating IOGD, a cation current activated during
prolonged oxygen-glucose deprivation, OGD [68]. In this
model of hypoxia using mouse cortical neurons, it was proposed
that ROS produced during oxidative stress activated TRPM7
channels, permitting the unregulated influx of Ca2+ and
triggering a vicious loop because high intracellular Ca2+ caused
the production of more ROS, increasing IOGD/TRPM7 activa-
tion. Downregulating TRPM7 expression by small interfering
RNA (siRNA) specific to TRPM7 protected the cells fromoxygen and glucose deprivation-induced stress. However, that
same TRPM7-specific siRNA also downregulated TRPM2
channels. This result was explained as suggestive of inter-
dependent protein expression between these two channels and/
or that they form heteromers in cortical neurons and that the
observed anoxia-induced current is carried by TRPM2/TRPM7
heteromers. The existence of the latter remains to be established
and to the best of our knowledge, interaction between TRPM2
and TRPM7 at a protein level has not yet been demonstrated.
The fact that oxidative and nitrative stressors activate
TRPM2 is clearly established [90,91] and will be discussed in
more detail later. Unfortunately, we have not seen H2O2-
mediated activation of human TRPM7 expressed in HEK-293
cells in our whole-cell patch clamp experiments, in the presence
of physiological concentrations of Ca2+ and Mg2+. We offer an
alternative explanation for the results observed in this OGD
study. As far as we can ascertain, these experiments were
conducted in the absence of external Mg2+. As we discussed in
the preceding section, this condition favors Ca2+ entry through
the constitutively open TRPM7 channels. The degree of Ca2+
influx will be determined by the number of TRPM7 channels
available for permeation that is in turn dependent on existing
levels of intracellular Mg2+ and MgATP. The experimental
induction of OGD causes significant reduction of cellular
MgATP [92] thereby lessening intracellular TRPM7 block. As
more TRPM7 channels become available for permeation,
intracellular Ca2+, [Ca2+]i, will rise. One of the consequences
of this [Ca2+]i rise will be increased ROS production in the
mitochondria. The combined [Ca2+]i rise and increased
oxidative stress is conducive to TRPM2 activation. In this
scenario, the activation of TRPM2 causes the massive influx of
Ca2+ and Na2+ that precedes cell death. This explanation is not
in conflict with the protective effect observed following siRNA
inhibition of TRPM7 because the early [Ca2+]i rise needed to
trigger ROS production will not occur when the number of
available TRPM7 channels is severely depleted. Thus, as the
authors concluded, TRPM7 is a critical and important player in
OGD-mediated neuronal death. It will be of interest to know
whether the IOGD pathway mediates neuronal death in the
presence of physiological and/or pathological (low) levels of
Mg2+. These are early days in the functional characterization of
TRPM channels, especially in the context of complex cells such
as neurons. Our best experimental attempts and interpretations
are limited by what we know, and in the case of TRPM7 and
TRPM2, there is much to learn. We need to know whether these
two channels form heteromers, what splice variants are
expressed in neuronal cells and under what conditions these
are expressed, the electrophysiological signature of the hetero-
mers, and the players involved in the modulation and activation
of homomeric and heteromeric channels. IOGD could be
mediated by both TRPM7 and TRPM2. Only time and more
studies will tell.
Nevertheless, given that this is a review on candidate
susceptibility genes for a form of neurodegenerative motor
neuron disease, the finding that TRPM7 is involved in neuronal
death is relevant. Importantly, the recently published study
describing the localization of TRPM7 in synaptic terminals of
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during neurotransmitter release in neuromuscular synapses [71]
adds further justification for considering TRPM7 as a good
candidate susceptibility gene for Western Pacific ALS/PD.
6. TRPM7 in Guam ALS/PD
6.1. The T1482I TRPM7 variant in Guamanian ALS/PD.
In an effort to identify a genetic variant that confers
susceptibility to ALS/PD, we sequenced genomic DNA from
ALS/PD samples and age-matched controls [93]. We found a
heterozygous variant of TRPM7 in a subset of Guamanian ALS/
PD cases encoding a channel protein with a missense mutation,
Thr1482 is replaced with Ile1482. Alignment of TRPM7 sequen-
ces from various species showed that Thr1482 is evolutionarily
conserved from zebrafish to humans, except in the mouse which
has serine (Ser) in this position. Thr and Ser are not dissimilar
since both can be phosphorylated. The evolutionary conserva-
tion of Thr/Ser in this position suggests that phosphorylation of
this residue is important and underscores the potential
significance of the Thr-to-Ile substitution because isoleucine
cannot be phosphorylated. TRPM7 is a Ser/Thr α-kinase, it
phosphorylates Ser and Thr residues in α-helices. We compared
phosphothreonine levels between wild-type (WT) and T1482I
TRPM7 and found that Thr1482 is indeed autophosphorylated.
The Thr-to-Ile substitution did not affect TRPM7 kinase activity
but increased the channel's sensitivity to intracellular Mg2+
block. Since one of the primary functions of TRPM7 is report-
edly the cellular import of Mg2+ and Ca2+, cells expressing
T1482I will conceivably become more deficient in these ions.
This deficiency will be more pronounced in an environment
severely depleted of Mg2+ and Ca2+ to begin with, such as
found in the hyperendemic ALS/PD foci in the Western Pacific.
It is our hypothesis, therefore, that the T1482I variant confers a
genetic predisposition to ALS/PD. In an environment with
normal levels of Ca2+ and Mg2+, severe deficiency does not
occur, but prolonged exposure to a conducive environment (in
this case one with very low Mg2+ and Ca2+ levels) unmasks the
deleterious effects of the mutation. The resulting imbalance in
Mg2+ and Ca2+ homeostasis could affect many cellular
processes including those responding to increased oxidative
stress and those causing activation of proinflammatory path-
ways. Unfortunately, testing this hypothesis is not so simple.
TRPM7 knockout in mice is embryonic lethal (A. Ryazanov,
personal communication). Moreover, there is the additional
complication that Thr1482 is replaced by Ser in the mouse. We
are exploring other possibilities such as using a DT20 chicken
lymphocyte cell line with the endogenous TRPM7 knocked-out
and replaced with inducible T1482I TRPM7 (in collaboration
with Drs. C. Schmitz and A. Perraud, National Jewish Medical
and Research Center), although we fully recognize that this is an
over-expression model. Given the newly described role of
TRPM7 in neurotransmitter release in the neuromuscular
junction, it will also be of interest to investigate whether
synaptic transmission is affected in the presence of T1482I,
especially given that disruption and loss of neuromuscularsynapse has been reported as one of earliest pathological events
in ALS and occurs long before the appearance of symptoms
[94,95].
6.2. Mg2 deficiency increases oxidative stress
The demonstration that low Mg2 conditions caused sig-
nificant loss of rat dopaminergic nigral neurons lends support to
the notion that neuropathological changes could ensue simply
as a result of prolonged exposure to low Mg2 [27]. What is the
possible mechanism behind this? Low Mg2+ caused lipid
peroxidation and activation of NF-κB in canine primary
cerebral vascular smooth muscle cells [59]. Lipid peroxidation
disrupts membrane integrity by damaging phospholipids and
furthermore, increases oxidative stress through the production
of reactive byproducts such as lipid hydroperoxides and reactive
aldehydes [60]. The peroxidation of mitochondrial membrane
lipids can alter the ionic balance in the mitochondria, causing
mitochondrial swelling and increased production of ROS [96].
NF-κB activation induced by low Mg2+ conditions can initiate
proinflammatory reactions such as induction of COX2 and
iNOS in microglia, keeping them in a persistent activated state
that is detrimental to surrounding neurons. Still another way that
low extracellular Mg2+ levels can impact the cell negatively is
through increased Ca2+, Na+, and metal influx through TRPM7,
as a result of there being less Mg2+ to impose external block.
Indeed we have seen increased Mn2+ influx through recombi-
nant TRPM7 when extracellular Mg2+ is lowered (M.
Hermosura and S. Thompson, unpublished data). Metals are
redox catalysts, and will therefore contribute to the rise in
cellular oxidative stress. That Mg2+ deficiency causes possible
alterations in ion fluxes and increased oxidative stress was also
suggested by gene expression studies in weaning rats exposed
to Mg2+-deficient diets [97].
Thus, the overall effect of lowMg2+ is to create conditions of
high oxidative stress that is conducive to the activation of
TRPM2, nonselective cation channels that have been linked to
the activation of cell death pathways [46,47,90,98,99].
7. Oxidative stress in Western Pacific ALS/PD
Factors emanating from the unique mineral composition of
the environment in the ALS/PD foci in the Western Pacific
converge to produce a state of high oxidative stress. Oxidative
stress is increasingly recognized as a key player in the initiation
and amplification of the disease process in many disorders
including neurodegenerative diseases [100] and underlies the
growing interest in our next candidate gene, TRPM2.
8. TRPM2 is an ion channel that is activated by oxidative
and nitrative stress
TRPM2 channels are cation nonselective channels that are
highly expressed in the brain and in immune cells, especially
those of monocytic lineage [101,102]. In a recent report,
RTPCR was used to demonstrate widespread distribution of
TRPM2 mRNA in the CNS [103]. In situ hybridization studies
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cerebral cortex, thalamus, and midbrain [104]. On a cellular
level, TRPM2 was shown to be expressed in neuronal cells and
microglial cells [46,104,105]. As mentioned earlier, TRPM2 is
one of only three known chanzymes, channels intrinsically
coupled to an enzyme domain. In TRPM2, the enzyme is in the
C-terminal region and is designated NUDT9-H to reflect its
homology to NUDT9 ADP-ribose hydrolase [106]. Although
low level NUDT9-H enzymatic activity has been demonstrated,
experimental data indicate that enzyme activity is not a
requirement for channel gating [107]. Instead, studies indicate
that NUDT9-H provides a binding site for adenine 5′-dipho-
sphoribose (ADPR), the physiological activator of TRPM2
[108]. In addition to ADPR, millimolar concentrations of β-
NAD have been shown to activate these channels [90,101].
Because of the high, non-physiological dose needed, the
suggestion that β-NAD could directly gate TRPM2 has been
questioned. It was instead proposed that TRPM7 activation by
β-NAD occurs as a result of β-NAD breakdown into ADPR
[109].
ADPR activation of TRPM2 is modulated by intracellular
Ca2+ [110,111]. Ca2+, by itself, cannot gate TRPM2 [111].
However, Ca2+ is required for basal levels of ADPR to gate the
channel. In granulocytes, basal ADPR was determined to be
∼5 μM, and it remained around this level even after agonist
stimulation. Ca2+ enhanced TRPM2 activation by ADPR. At a
given ADPR concentration, higher [Ca2+]i levels elicit larger
TRPM2 currents, with a reported EC50 of 340 nM [110]. It was
thus proposed that APPR and Ca2+ act in concert, as a second
messenger system, to transduce the effects of agonist binding.
The enhancing effect of Ca2+ on TRPM2 activation may be
relevant in connection with oxidative stress-mediated neuronal
death as discussed below.
9. TRPM2 in oxidative stress-mediated cell death
Accumulating evidence suggests that TRPM2 plays a central
role in oxidative stress-mediated cell death [46,98,99,112].
H2O2-mediated death of cerebral cortical neurons was sig-
nificantly reduced following siRNA inhibition of TRPM2 [46].
Similarly, H2O2-induced toxicity in striatal neurons was
attenuated upon transfection with a dominant negative short
form of TRPM2 (TRPM2-S) as well as TRPM2-specific siRNA
inhibition [113,114]. In both cases, death was preceded by a rise
of intracellular Ca2+ as a result of massive Ca2+ influx through
TRPM2 channels. How oxidative and nitrative stressors activate
this channel remains controversial as different studies support
different candidate pathways. Nevertheless, existing possibili-
ties can be broadly classified as direct and indirect. In the
former, H2O2 gates the channel directly [91,104]. In the indirect
pathway, TRPM2 activation is ADPR-gated, with oxidative
stress simply increasing production of this metabolite. Experi-
mental evidence supports at least two different mechanisms
through which intracellular ADPR levels are raised during
oxidative stress: one mediated by poly(ADP-ribose) polymerase
(PARP) and the other through production of ADPR in the
mitochondria by way of β−NAD breakdown [115,116]. Finally,it is also possible that oxidative stress-induced [Ca2+]i rise could
simply enhance ADPR-mediated activation of TRPM2, without
any added production of ADPR [111]. As is often the case,
existing in situ conditions, including cell type-specific metabolic
factors dictate which pathway or pathways are recruited and it is
highly likely that more than one is operating in a given situation.
For example, PARP enzymatic activity and β−NAD breakdown
could be happening simultaneously, increasing cytoplasmic
ADPR levels. At the same time, oxidative stress-induced [Ca2+]i
rise enhances ADPR-mediated activation of TRPM2 channels.
All these pathways could converge to create a situation where
sustained Ca2+ influx occurs.
9.1. TRPM2 is permeable to Na+ and other cations
It must be remembered, however, that TRPM2 is cation
nonselective and that other ions (propelled by their own
electrochemical driving force) permeate the channel alongside
Ca2+. Foremost among these is Na+. The impact of massive Na+
influx through TRPM2 has not been carefully assessed but one
can envision that the ensuing membrane depolarization will
exert a significant effect especially in excitable cells such as
neurons and pancreatic β-cells. Sudden large changes in
cytoplasmic Ca2+ and Na+ levels after TRPM2 activation
could be severely detrimental to proper mitochondrial function.
One of these functions, buffering pathophysiological [Ca2+]i
rises such as those evoked by oxidative stress, could be
particularly susceptible because it is partly dependent on a Na+/
Ca2+ exchanger in the mitochondrial inner membrane [117].
Disruption in exchanger function could affect ionic homeostasis
in the mitochondria, causing mitochondrial swelling and other
adverse effects, among them reducing the half-life of mito-
chondrially encoded RNA [96,118]. Mitochondrial swelling is
an early preclinical feature in neurodegenerative diseases,
including ALS [119]. Strongly supporting this thesis is the
recent demonstration that brain and spinal cord mitochondria in
two familial ALS (SOD1) mouse models exhibit reduced Ca2+
buffering capacity. Importantly, this decrease occurred very
early in the course of the disease, prior to the onset of symptoms
[120].
TRPM2 channels are cation nonselective and could therefore
conduct transition metals, in addition to Na+ and Ca2+. Indeed,
Mn2+ permeation has been demonstrated using fura-2 quench
experiments [90]. We recently completed studies where we used
the zinc-specific dye, FluoZin-3, to demonstrate Zn2+ influx
through TRPM2 (R. Go, C. Shetler, S. Thompson and M.
Hermosura, unpublished data). The finding that TRPM2 could
allow permeation of Mn2+ and Zn2+ is especially significant
when viewed in the context of the possible role of TRPM2 in
neurodegeneration because the abnormal accumulation of these
metals has been associated with neuropathology [121]. A
seminal paper on ALS/PD reported that the Mn2+ content in the
spinal cord was 10–20 × higher in ALS patients than in controls
[13]. The abnormal cellular accumulation of Zn2+ has been
linked to acute neuronal damage during ischemia and epilepsy,
as well as with pathologic changes in neurodegenerative
diseases [122]. A recent reassessment of metal accumulation
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brain samples [123]. Altered metal homeostasis has also been
described in sporadic as well as familiar ALS [124,125]. The
proper regulation of metal homeostasis relies on a delicate
balance between influx, sequestration by cellular buffer
systems, and transport out of the cell. Transition metals are
redox-active, capable of stimulating free radical formation thus
increasing cellular oxidative stress. Therefore, transition metals
entering through TRPM2 (and other influx pathways) create
conditions conducive to more TRPM2 activation, further tilting
the balance in favor of ion influx which is dominated by the
physiologically abundant Ca2+ and Na+ ions. The ensuing
increase in cytoplasmic Ca2+ and Na+ levels could cause
mitochondria to generate more ROS, thus creating a vicious
loop that could overwhelm the cell's protective machinery.
10. Mitochondrial dysfunction in ALS
We have seen that as a consequence of its activation, TRPM2
can affect the proper functioning of the mitochondria.
Mitochondrial dysfunction has been reported as a potential
contributory factor in sporadic and familial ALS [118–
120,126–129]. Unfortunately, this subject was not investigated
early on in connection with Western Pacific ALS/PD, except for
one mention of a possible complex I deficiency [130] and
reports of degenerating mitochondria in ultrastructure studies on
brain sections from autopsy specimens and animal models fed
low Ca2+ and Mg2+ diets [22–27]. It appears that brain and
spinal cord mitochondria are particularly susceptible to the
disease process in ALS. In SOD1 models of ALS, diminished
Ca2+ buffering capacity was only detected in brain and spinal
cord, not in liver mitochondria [120]. Possible reasons for the
unusual sensitivity of spinal cord mitochondria are their
significantly lower threshold for Ca2+-induced change in
mitochondrial permeability transition (MPT), increased sus-
ceptibility to lipid peroxidation, reduced mitochondrial mRNA
levels, and significantly higher levels of oxidized mitochondrial
DNA [131].
Somatic mutations could contribute significantly to mito-
chondrial dysfunction. Mitochondrial DNA (mtDNA) is a 16.5-
kb circular genome that encodes 13 proteins of the respiratory
chain and 22 tRNAs. It lacks protective histones and is therefore
more susceptible to oxidative damage than nuclear DNA. The
high oxidative state in this organelle is expected to heavily favor
more mutations. Increased frequencies of mtDNA mutations
have been reported in sporadic ALS and other neurodegenera-
tive diseases [118,127,132]. It was proposed that some of these
mutations reduce complex IV activity of the electron transport
chain (ETC). MtDNA from ALS subjects transferred to
mtDNA-depleted human neuroblastoma cells caused abnormal
ETC function, perturbed Ca2+ homeostasis, and alterations in
mitochondrial structure [133]. We recently sequenced mtDNA
from ALS/PD and found somatic mutations in the light strand
promoter (LSP) region in mitochondrial DNA of brain tissue
from both PD [134] and ALS patients [R. Garruto et al.,
unpublished data]. The LSP exerts regulatory control over
mitochondrial transcription and replication. Its crucial role inmaintaining the stability of the mitochondrial genome implies
that mutations in the LSP could be detrimental to proper
mitochondrial function.
It has been suggested that mitochondria could act both as
target and trigger in sporadic and familial ALS [135]. The
apparent functional connection between TRPM2 and mitochon-
dria lends support to this suggestion. Sudden increases in
cytoplasmic Ca2+ and Na+ mediated by TRPM2 that could be
handled routinely by normally functioning mitochondria could
be detrimental to mitochondria where somatic mutations have
caused dysfunctional ETC activities, or where lipid peroxidation
has affected membrane integrity, rendering the organelle much
less capable of handling ion imbalances. It is possible that higher
levels of ROS are produced in these situations, causing persistent
TRPM2 activation, and sustained massive Ca2+ and Na+ influx,
that could overwhelm cellular buffering systems. The self-
sustaining cycle of oxidative stress, [Ca2+]i rises, elevated ROS,
and increased TRPM2 activation, could be responsible for
generating sustained Ca2+ influx. In the presence of dysfunc-
tional mitochondria with diminished Ca2+ buffering capacities,
abnormally high Ca2+ will accumulate. This series of events may
underlie the abnormal accumulation of Ca2+ observed in the
cytoplasm and mitochondria in brain and spinal cord tissues in
ALS/PD and the other clinical variants of ALS [19,23,136].
Motor neurons are particularly vulnerable to Ca2+ overload
because of a low cytosolic Ca2+ buffering capacity [119,137]. It
is therefore reasonable to assume that oxidative stress and
persistent activation of TRPM2 channels in motor neurons will
be particularly damaging. The recent demonstration that L-
BMAA-induced cytotoxic effects, [Ca2+]i rises, and ROS
production were substantially greater in motor than in other
spinal neurons strongly support this hypothesis [44]. Impor-
tantly, the finding that L-BMAA caused substantial [Ca2+]i rise
and ROS production in motor neurons, conditions conducive to
TRPM2 activation, suggests a possible role for TRPM2 in L-
BMAA mediated neurotoxicity. TRPM2 function in motor
neurons, especially in the presence of L-BMAA and other
oxidative stressors, is a particularly important topic for future
research.
11. Immune involvement in ALS: TRPM2 in microglia
There is increasing evidence that the degeneration and death
of motor neurons in sporadic and familial ALS is not limited to
pathogenic processes within the neurons themselves, but
involves an immune component contributed by neighboring
cells, particularly microglia, the resident immunocompetent
cells in the CNS [138–144]. Microglia provide early response to
brain injury by releasing proinflammatory cytokines and toxic
factors such as nitric oxide (NO), H2O2, and ROS. Activated
microglia are phagocytic, possess enhanced migratory abilities
and have been observed in the spinal cord ventral horn of ALS
patients [145]. Microglial activity was not investigated in
connection with Western Pacific ALS/PD, although defects in
humoral and cellular immunity were reported [146, 147].
TRPM2 is highly expressed in microglia and more importantly,
it has been suggested that TRPM2 is involved in microglial
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information on microglial activation in ALS/PD, we will
discuss what is known about this topic in familial and sporadic
ALS.
Studies in sporadic ALS and in mouse models of familial
ALS suggest that immune events occur at a very early stage in
the disease process. Microglial proliferation and activation has
been shown to precede and contribute to neuronal death [141].
Proinflammatory factors, presumably secreted by microglia,
were detected at an early stage, when no motor neuron loss had
yet occurred. Cerebrospinal fluid (CSF) in sporadic and familial
ALS contains cytotoxic factors [142], one of which is 4-
hydroxynonenal (4-HNE), a reactive aldehyde byproduct of
lipid peroxidation [143]. It is becoming increasingly clear that
interactions between motor neurons and surrounding glial cells
are integral to ALS pathogenesis [138–140,148–150]. For
instance, a study using the G93A SOD1 model of familial ALS
reported that disease only ensued when the mutation was
expressed in both human glioblastoma and neuroblastoma cells,
not when expression was restricted to either cell type [148].
Another study used a cell culture system to demonstrate motor
neuron toxicity induced by lipopolysaccharide (LPS)-activated
microglia [149]. Toxicity appeared to be caused by microglial-
induced oxidative/nitrative stress activating a Ca2+ influx
pathway, because it was prevented by a microglial inducible
nitric oxide synthase (iNOS) inhibitor, the removal of
extracellular Ca2+, or by the addition of catalase or glutathione.
Finally, definitive involvement of microglia in the disease
process in familial ALS was demonstrated using transgenic
mice with deletable mutant SOD1 [139]. ‘Turning down’
mutant SOD1 expression in motor neurons substantially
delayed disease onset and early progression. Applying the
same manipulation to microglia did not affect disease onset but
greatly slowed later disease progression and extended overall
survival suggesting that microglia with mutant SOD1 accelerate
the disease process.
Microglial activation is mediated through increases in
cytoplasmic Ca2+ originating from intracellular stores and
from the extracellular environment [104,151]. TRPM2 channels
were shown to contribute significantly to the latter. Importantly,
TRPM2 in activated microglia were shown to exhibit
heightened sensitivity to H2O2 [104]. Activated microglia,
however, produce H2O2 themselves (a process called respira-
tory burst). Therefore, the heightened sensitivity of TRPM2 to
H2O2 in activated microglia will likely serve as a positive
feedback signal, promoting more TRPM2 activation and
sustained Ca2+ and Na+ influx, conditions that can keep
microglia in a prolonged activated state. Such an occurrence
will generate oxidative stress in neighboring neurons and glia.
The combined effect of oxidative stress, subsequent TRPM2
activation, and drastic increase of cellular Ca2+ and Na+ levels
will be particularly detrimental to motor neurons because of
their inability to buffer huge cytoplasmic Ca2+ changes.
Abnormal Ca2+ accumulation in motor nerve terminals in
ALS lends support to this possible scenario [152] and to the
hypothesis that increased intracellular Ca2+ triggered by
immune mechanisms is involved in motor neuron cell deathin ALS [153]. Dense populations of microglia are reportedly
present in the hippocampus, olfactory telencephalon, basal
ganglia, and substantia nigra [154]. Following the reasoning
presented above, it can be surmised that these brain regions will
be more susceptible to damage due to prolonged microglial
activation. The selective loss of nigral cells after prolonged
exposure to low Mg2+ lends support to this possibility [27].
Increased oxidative stress and NF-κB activation brought about
by low Mg2+ could cause persistent microglial activation and
nigral cell damage.
It is certainly likely that other Ca2+ influx pathways such
AMPA/Kainate and glutamate receptors are also involved.
However, the direct relationship evident in the ‘microglia-
oxidative stress-motor neuron TRPM2-Ca2+ influx pathway’
appears to be a plausible hypothesis, particularly in explaining
the relationship between microglia and motor neurons and
immune involvement in the pathogenesis of ALS [155,156].
12. Other intriguing clues to TRPM2 involvement in
ALS/PD
12.1. β-amyloid peptides
These peptides have been linked to the etiology of AD and
have also been found in ALS/PD. A recent study reported that
β-amyloid activity is mediated through TRPM2 channels [111].
12.2. Diabetic peripheral neuropathy in ALS/PD and the role
of PARP activation
In 1997, a possible relationship between diabetes mellitus
and ALS/PD in Guam was noted [130]. A study published in
1999 reported that peripheral neuropathy may be a manifesta-
tion of Guamanian ALS/PD [157]. The activation of poly(ADP-
ribose) polymerase (PARP) has recently been identified as an
important mechanism underlying peripheral diabetic neuro-
pathy [158]. PARP activation has also been identified as one of
the major pathways whereby oxidative stress activates TRPM2
channels [115] suggesting that Ca2+ influx via TRPM2 may be
involved in peripheral diabetic neuropathy. Importantly, these
results strongly support that suggestion that Guam ALS/PD is a
multisystem disorder with a subclinical involvement of the
peripheral nervous system and that unregulated TRPM2
activation, perhaps due to high oxidative stress, may be a key
etiological factor.
12.3. TRPM2 mutants in ALS/PD
Sequence analysis of TRPM2 revealed the presence of three
variants associated with ALS/PD. The results are being written
for publication and will not be covered in this review.
13. Summary
A great deal of effort and major resources have been dedi-
cated to the study of Western Pacific ALS/PD. The substantial
amount of neuropathological, clinical, and epidemiological data
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information and clues that could be analyzed and interpreted in
conjunction with more recent studies on sporadic and familial
ALS. It is generally accepted that the different clinical variants
of ALS likely share similar molecular pathogenic mechanisms
and of these, the preponderance of evidence suggests the
involvement of oxidative stress, mitochondrial dysfunction,
aberrant Ca2+ homeostasis, and immune mechanisms, primarily
mediated by activated microglia.
By virtue of their activation and permeation properties and
the fact that they are expressed in motor neurons and microglial
cells, we present TRPM7 and TRPM2 as candidate susceptibility
genes in ALS/PD, and perhaps for sporadic ALS, as well.
TRPM7 and TRPM2 channel activities are interconnected with
the principal factors suspected of involvement in these diseases:
aberrant Ca2+ and Mg2+ homeostasis, mitochondrial dysfunc-
tion, oxidative stress, and inflammatory responses. It can be
hypothesized, therefore, that genetic variants of these channels
could affect any or all of the suspected mechanisms and thus
contribute to the disease process. While there are certainly
conjectures and suppositions based on circumstantial evidence,
we nevertheless hope that we have identified two promising
targets for future research.
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